Search Demo - PsychoGenics

To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.

Functional Always active

The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.

Preferences

The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.

Statistics

The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.

Marketing

The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.

Filters

Filters

Therapeutic Areas

Specific Disorders

Filters

Genetic Deletion of Transglutaminase 2 Does Not Rescue the Phenotypic Deficits Observed in R6/2 and zQ175 Mouse Models of Huntington’s Disease

Phenotypic Characterization of Recessive Gene Knockout Rat Models of Parkinson’s Disease

High-Throughput Automated Phenotyping of Two Genetic Mouse Models of Huntington’s Disease.

Regional Vulnerability in Huntington’s disease: fMRI-guided Molecular Analysis in Patients and a Mouse Model of disease

Comprehensive Behavioral and Molecular characterization of a new knock-in Mouse Model of Huntington’s disease: zQ175

Insights into the Structural Determinants Required for High Affinity Binding of Chiral Cyclopropane-Containing Ligands to α4β2-Nicotinic Acetylcholine Receptors; An Integrated Approach to Behaviorally Active Nicotinic Ligands.

Functional Improvement in Mouse Models of Familial Amyotrophic Lateral Sclerosis by PEGylated insulin-like Growth Factor I Treatment Depends on Disease Severity .

Prediction of Death in the SMNΔ Mouse Model of Spinal Muscular Atrophy: Insight into Disease Stage and Progression. Journal of Neuroscience Methods.

Identification of a Maleimide-Based Glycogen Synthase Kinase-3 (GSK-3) Inhibitor, BIP-135, that Prolongs the Median Survival Time of Ä7 SMA KO Mouse Model of Spinal Muscular Atrophy.

Let’s Find the Right Solution Together

Quick Links

Contact

Address

Email

Phone

Fax